Dabigatran: eine neue Option zur Therapie und Prophylaxe thrombembolischer Erkrankungen?

Schlüsselwörter

Dabigatran - Thrombose - direkter Thrombininhibitor

Keywords

dabigatran - thrombosis - direct thrombin inhibitor

Literatur

• 1 Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans.  Drug Metab Dispos. 2008;  36 386-399
• 2 Cohen A T, Tapson V F, Bergmann J F, Goldhaber S Z, Kakkar A K, Deslandes B, Huang W, Zayaruzny M, Emery L, Anderson Jr F A. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study.  Lancet. 2008;  371 387-394
• 3 Connolly S J, Ezekowitz M D, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly P A, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis B S, Darius H, Diener H C, Joyner C D, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation.  N Engl J Med. 2009;  361 1139-1151
• 4 Di Nisio M, Middeldorp S, Buller H R. Direct thrombin inhibitors.  N Engl J Med. 2005;  353 1028-1040
• 5 Eriksson B I, Dahl O E, Rosencher N, Kurth A A, van Dijk C N, Frostick S P, Kalebo P, Christiansen A V, Hantel S, Hettiarachchi R, Schnee J, Buller H R. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.  J Thromb Haemost. 2007;  5 2178-2185
• 6 Eriksson B I, Dahl O E, Rosencher N, Kurth A A, van Dijk C N, Frostick S P, Prins M H, Hettiarachchi R, Hantel S, Schnee J, Buller H R. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.  Lancet. 2007;  370 949-956
• 7 Hirsh J, Dalen J, Anderson D R, Poller L, Bussey H, Ansell J, Deykin D. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.  Chest. 2001;  119 8S-21S
• 8 Hirsh J, Dalen J E, Deykin D, Poller L, Bussey H. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range.  Chest. 1995;  108 231S-246S
• 9 Kubitza D, Haas S. Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases.  Expert Opin Investig Drugs. 2006;  15 843-855
• 10 Liesenfeld K H, Schafer H G, Troconiz I F, Tillmann C, Eriksson B I, Stangier J. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis.  Br J Clin Pharmacol. 2006;  62 527-537
• 11 Stangier J, Eriksson B I, Dahl O E, Ahnfelt L, Nehmiz G, Stahle H, Rathgen K, Svard R. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement.  J Clin Pharmacol. 2005;  45 555-563
• 12 Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.  Br J Clin Pharmacol. 2007;  64 292-303